AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2521930
Drug: Secondary prevention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secondary prevention program including physical and behavioral therapy
Trial: 28030526
Drug: JE chimeric
RxNorm normalized name: Japanese encephalitis virus vaccine Nakayama-NIH strain, inactivated Injectable Suspension [Je-Vax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JE chimeric virus vaccine (JE-CV)
Trial: 21868794
Drug: NSAIDs, physiotherapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAIDs, physiotherapy, and local steroid injection (group 2B)
Trial: 15239872
Drug: Elective change
RxNorm normalized name: hetastarch
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elective change of intravenous cannulae every 48 hours
Trial: 11122017
Drug: Liarozole 50
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liarozole 50 mg
Trial: 11122017
Drug: Liarozole 75
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liarozole 75 mg
Trial: 11122017
Drug: Liarozole 150
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liarozole 150 mg
Trial: 9124990
Drug: Piperacillin/tazobactam (P/T)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin/tazobactam (P/T) administered as dropwise intravenous infusions in a single dose of 4/0.5 g 3 times a day for 5 to 17 days
Trial: 8249561
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg tetracaine diluted in 1 ml of 10% glucose
Trial: 8249561
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg tetracaine diluted in 2 ml of 10% glucose
Trial: 8249561
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg tetracaine diluted in 4 ml of 10% glucose
Trial: 3524172
Drug: Moricizine therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moricizine therapy (10 mg/kg/day)
Trial: 3524172
Drug: Moricizine therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moricizine therapy
Trial: 29802630
Drug: Implants with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implants with keratinized mucosa (Group 1)
Trial: 29802630
Drug: Implants without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Implants without keratinized mucosa (Group 2)
Trial: 27203434
Drug: Bevacizumab (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (1.25 mg, monthly intravitreal injections for one year)
Trial: 27203434
Drug: Ranibizumab (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab (0.5 mg, monthly intravitreal injections for one year)
Trial: 18541933
Drug: DOTS (thrice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DOTS (thrice weekly for 2 months, followed by isoniazid and rifampicin thrice weekly for 4 months)
Trial: 18541933
Drug: Daily tuberculosis
RxNorm normalized name: Mycobacterium tuberculosis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily tuberculosis chemotherapy (daily for 2 months, followed by isoniazid and rifampicin daily for 7 months)
Trial: 18541933
Drug: Daily tuberculosis
RxNorm normalized name: Mycobacterium tuberculosis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily tuberculosis chemotherapy
Trial: 10235547
Drug: Nilvadipine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nilvadipine (4 mg/d) orally in NTG patients
Trial: 10235547
Drug: Control (vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (vehicle solution) in rabbits
Trial: 8907805
Drug: Indapamide 2.5
RxNorm normalized name: indapamide 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indapamide 2.5 mg daily for 12 weeks
Trial: 8907805
Drug: Captopril 37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 37.5 mg daily for 12 weeks
Trial: 1905384
Drug: Quantitative methods
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quantitative methods to measure drug usage
Trial: 6342563
Drug: Interpersonal psychotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interpersonal psychotherapy (IPT), consisting of weekly individual psychotherapy for six months
Trial: 6342563
Drug: Low-contact treatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-contact treatment, consisting of one brief meeting per month for six months
Trial: 15346948
Drug: Immunotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy with polycomponent vaccine VP-4 (4 or 5 subcutaneous injections at an interval of 5-7 days)
Trial: 15346948
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving basic therapy
Trial: 12190996
Drug: Miglitol 100
RxNorm normalized name: miglitol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miglitol 100 mg three times a day for 2 days (six doses total)
Trial: 9807740
Drug: Allogeneic cell
RxNorm normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allogeneic cell therapy (AlloCT) with human recombinant interleukin 2 (rIL-2) for 3 days to activate donor PBL, followed by infusion of in vitro rIL-2 activated donor lymphocytes combined with 3-day rIL-2 therapy.
Trial: 9807740
Drug: Allogeneic cell
RxNorm normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allogeneic cell therapy (AlloCT) with donor marrow cell infusion without further conditioning.
Trial: 7622801
Drug: Mirtazapine (24‐72
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirtazapine (24‐72 mg/day)
Trial: 7622801
Drug: Trazodone (150‐450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazodone (150‐450 mg/day)
Trial: 9663810
Drug: Selegiline 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selegiline 10 mg
Trial: 320476
Drug: Granulocyte transfusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte transfusion in addition to antibiotics
Trial: 320476
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received appropriate antibiotic regimen alone
Trial: 6753860
Drug: Ciprofibrate 50
RxNorm normalized name: ciprofibrate
DrugBank: Ciprofibrate (DB09064)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofibrate 50 mg/day
Trial: 6753860
Drug: Ciprofibrate 100
RxNorm normalized name: ciprofibrate 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofibrate 100 mg/day
Trial: 30554519
Drug: Monthly injectable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly injectable PrEP
Trial: 25152283
Drug: Ultrasound-guided bilateral
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided bilateral transversus abdominis plane block with 0.25% ropivacaine 60 ml (group A)
Trial: 22246200
Drug: 5-Fluorouracil (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-Fluorouracil (50 mg/ml)
Trial: 18206039
Drug: Alprazolam (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (0.4 mg qd at 10PM for 3 days, n = 72)
Trial: 15234399
Drug: Pre-treatment with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment with clopidogrel for three days
Trial: 15234399
Drug: Standard post-procedural
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Standard post-procedural treatment (Control)
Trial: 11383794
Drug: Pentoxifylline (PTX)
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (PTX) 300 mg bolus followed by 1.5 mg.kg(‐1).h(‐1) continuous infusion for 2 days
Trial: 8364942
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of ketorolac tromethamine
Trial: 8364942
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of hydrocodone plus 1000 mg of acetaminophen
Trial: 28746076
Drug: Neublastin 50
RxNorm normalized name: NEUBLASTIN
DrugBank: Artemin (DB15438)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neublastin 50 μg/kg
Trial: 28746076
Drug: Neublastin 1200
RxNorm normalized name: NEUBLASTIN
DrugBank: Artemin (DB15438)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neublastin 1200 μg/kg
Trial: 28746076
Drug: All neublastin
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All neublastin doses
Trial: 26135333
Drug: Nicotine nasal
RxNorm normalized name: nicotine Nasal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine nasal spray during follicular phase (F)
Trial: 26135333
Drug: Nicotine nasal
RxNorm normalized name: nicotine Nasal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine nasal spray during luteal phase (L)
Trial: 25713924
Drug: Video capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Video capsule endoscopy (VCE) using the PillCam SB capsule endoscopy system
Trial: 22811030
Drug: Sodium nitrate
RxNorm normalized name: Sodium Nitrate
DrugBank: Sodium nitrate (DB15952)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium nitrate supplementation (10 mg·kg of body mass)
Trial: 17503683
Drug: Provider responses
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Provider responses to computer alerts regarding guideline recommendations for antihypertensive treatment.
Trial: 11349696
Drug: 5 mg/dose
RxNorm normalized name: Arixtra 5 mg/dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/dose
Trial: 11349696
Drug: 10 mg/dose
RxNorm normalized name: Arixtra 10 mg/dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/dose
Trial: 11349696
Drug: 15 mg/dose
RxNorm normalized name: Valtoco, 15 mg/dose nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/dose
Trial: 9484545
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of cisapride during fasting
Trial: 9484545
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of cisapride followed 30 minutes later by ingestion of 300 mL of milk
Trial: 9484545
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet during fasting
Trial: 9484545
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet followed 30 minutes later by ingestion of 300 mL of milk
Trial: 7869731
Drug: Benazepril 20
RxNorm normalized name: benazepril 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benazepril 20 mg plus Hydrochlorothiazide 25 mg (BN + HCT)
Trial: 7869731
Drug: Captopril 50
RxNorm normalized name: captopril 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 50 mg plus Hydrochlorothiazide 25 mg (CP + HCT)
Trial: 22882673
Drug: Oral tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tramadol therapy (50 to 200 mg/day)
Trial: 22882673
Drug: Rescue analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rescue analgesia (topical cream with 3.33% doxepin and 0.05% capsaicin)
Trial: 21126595
Drug: Transplanted CD34(+)
RxNorm normalized name: CD34+ Cells
DrugBank: Autologous peripheral blood-derived CD34+ cells (DB16367)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transplanted CD34(+) cell dose levels: 2-4 × 10(6) cells/kg, 4-6 × 10(6) cells/kg, >6 × 10(6) cells/kg
Trial: 17668526
Drug: Clindamycin phosphate
RxNorm normalized name: Clindamycin Phosphate
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clindamycin phosphate 1.2% and tretinoin 0.025% gel (CLIN/RA gel)
Trial: 15479494
Drug: Paclitaxel 100
RxNorm normalized name: paclitaxel 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel 100 mg/m2 plus estramustine 280 mg orally 3 times a day
Trial: 15479494
Drug: Paclitaxel 100
RxNorm normalized name: paclitaxel 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel 100 mg/m2 alone
Trial: 9547441
Drug: Nebivolol 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol 5.0 mg
Trial: 9825177
Drug: d-nebivolol 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-nebivolol 2.5 mg
Trial: 9825177
Drug: l-nebivolol 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-nebivolol 2.5 mg
Trial: 9825177
Drug: Racemic nebivolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Racemic nebivolol (2.5, 5.0, and 10.0 mg)
Trial: 8074059
Drug: Nicotine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine (15 micrograms/kg) combined with caffeine (5 mg/kg) during activity
Trial: 8074059
Drug: Caffeine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (5 mg/kg) during activity
Trial: 2510845
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (20 mg elemental zinc daily)
Trial: 2510845
Drug: Placebo (capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (capsule identical in appearance and taste with inert substances)
Trial: 29231502
Drug: Auricular sticking
RxNorm normalized name: Zit Stick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auricular sticking therapy with semen vaccariae, applied every three days for 2 weeks, combined with western medication.
Trial: 29231502
Drug: Auricular pseudo-press
RxNorm normalized name: garden cress sprout extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auricular pseudo-press therapy, applied every three days for 2 weeks, combined with western medication.
Trial: 11325322
Drug: Tricyclic antidepressant
RxNorm normalized name: Tricyclic antidepressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tricyclic antidepressant medication (amitriptyline hydrochloride, up to 100 mg/d, or nortriptyline hydrochloride, up to 75 mg/d)
Trial: 11325322
Drug: Stress management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stress management therapy (3 sessions and 2 telephone contacts) plus placebo
Trial: 11325322
Drug: Stress management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stress management therapy plus antidepressant medication
Trial: 9513669
Drug: Intravenous tenoxicam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous tenoxicam 40 mg
Trial: 1884268
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of peroperative and postoperative transfusion (Group III)
Trial: 6411615
Drug: Intravenous fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous fat tolerance test
Trial: 6411615
Drug: Total parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total parenteral nutrition with fat dosage of 2.5 g/kg X d‐1
Trial: 31818053
Drug: Sports medicine
RxNorm normalized name: Mueller Sports Medicine Compression Glove
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sports medicine physician (SMP)
Trial: 28323797
Drug: Local vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Local vancomycin powder (up to a maximum dose of 1000 mg, placed immediately before wound closure)
Trial: 27475691
Drug: Fentanyl Transdermal
RxNorm normalized name: Fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl Transdermal System (FTS)
Trial: 27475691
Drug: Control (placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (placebo patch and analgesic)
Trial: 21037490
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acids (eicosapentaenoic acid and docosahexaenoic acid, 2 g/d)
Trial: 20110013
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of rebamipide 100 mg
Trial: 20110013
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of rebamipide 100 mg
Trial: 11234938
Drug: Insulin-dependent diabetics
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-dependent diabetics
Trial: 11234938
Drug: Non-insulin-dependent diabetics
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-insulin-dependent diabetics
Trial: 10225575
Drug: Ciprofloxacin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (100 mg bd for 3 days)
Trial: 10225575
Drug: Co-trimoxazole (160/800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-trimoxazole (160/800 mg bd for 7 days)
Trial: 10225575
Drug: Nitrofurantoin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrofurantoin (100 mg bd for 7 days)
Trial: 8059818
Drug: Monophasic combination
RxNorm normalized name: Monobasic Potassium Phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monophasic combination of 30 micrograms ethinyl estradiol and 75 micrograms gestodene (treatment group, n = 12)
Trial: 2741619
Drug: Continuous glucose-saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous glucose-saline infusion
Trial: 2741619
Drug: 5-hour glucose
RxNorm normalized name: Glucose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-hour glucose infusion
Trial: 2741619
Drug: Standardized intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized intravenous fluids
Trial: 26799528
Drug: Bone-level implants
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone-level implants with mucosal thickness ≤2 mm (Group A, MC)
Trial: 26799528
Drug: Bone-level implants
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone-level implants with mucosal thickness >2 mm (Group B, MC)
Trial: 26799528
Drug: Tissue-level implants
RxNorm normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tissue-level implants with mucosal thickness ≤2 mm (Group A, LC)
Trial: 26799528
Drug: Tissue-level implants
RxNorm normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tissue-level implants with mucosal thickness >2 mm (Group B, LC)
Trial: 25727892
Drug: Alkalosis (ALK;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alkalosis (ALK; 0.3 g (kg body weight)(-1) sodium bicarbonate)
Trial: 25727892
Drug: Placebo (PLA;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PLA; 0.3 g (kg body weight)(-1) calcium carbonate)
Trial: 18293426
Drug: Androgen deprivation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen deprivation therapy (ADT) as part of local treatment
Trial: 11261502
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg glatiramer acetate (GA)
Trial: 8300824
Drug: Glutathione therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutathione therapy (600 mg i.m. injection every other day for 2 months)
Trial: 8300824
Drug: Placebo (equal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (equal volume of a placebo preparation for 2 months)
Trial: 3814032
Drug: Atropine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine (4 mg X 70 kg‐1 body weight)
Trial: 3814032
Drug: 2-PAM chloride
RxNorm normalized name: 2-PAM chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-PAM chloride (up to 1200 mg X 70 kg‐1 body weight)
Trial: 27938540
Drug: H2∶O2 mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H2∶O2 mixture (66.67%∶33.33%) inhalation for 1 hour per day for 30 days
Trial: 27938540
Drug: N2∶O2 mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N2∶O2 mixture (66.67%∶33.33%) inhalation for 1 hour per day for 30 days
Trial: 24955451
Drug: 2-L polyethylene
RxNorm normalized name: Iron(2+) L-ascorbate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-L polyethylene glycol + ascorbic acid (PEG + Asc)
Trial: 24955451
Drug: 4-L polyethylene
RxNorm normalized name: polyethylene glycol 3350
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-L polyethylene glycol (4-L PEG)
Trial: 18436114
Drug: Darapladib 40
RxNorm normalized name: Darapladib
DrugBank: Darapladib (DB06311)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darapladib 40 mg
Trial: 26465780
Drug: Darapladib 160
RxNorm normalized name: Darapladib
DrugBank: Darapladib (DB06311)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darapladib 160 mg
Trial: 16573804
Drug: Eudragit-L-coated mesalazine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eudragit-L-coated mesalazine tablets
Trial: 16573804
Drug: Ethylcellulose-coated mesalazine
RxNorm normalized name: Ethylcellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethylcellulose-coated mesalazine tablets
Trial: 12679312
Drug: Dextromethorphan 60
RxNorm normalized name: DEXTROMETHORPHAN 60MG/GG 1200MG SA TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextromethorphan 60 mg BID
Trial: 12679312
Drug: Dextromethorphan 90
RxNorm normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dextromethorphan 90 mg BID
Trial: 12679312
Drug: Dextromethorphan 60
RxNorm normalized name: DEXTROMETHORPHAN 60MG/GG 1200MG SA TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextromethorphan 60 mg thrice daily